Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2020-02-14
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult
participants with moderate-to-severe atopic dermatitis (AD).
Secondary Objectives:
- To evaluate the safety of dupilumab monotherapy compared to placebo treatment in adult
participants with moderate-to-severe AD.
- To evaluate the effect of dupilumab on improving patient reported outcomes (PROs).
- To evaluate dupilumab immunogenicity.